Table 2: Crude and adjusted hazard ratio for the two groups in the 5-year follow-up period.

 Event %Unadjusted HRP  valueAdjusted HRP  value
(95% CI)(95% CI)

Cervical cancer patients with 3D treatment ( )67 (10.4)10.00810.009
Cervical cancer patients with 2D treatment ( )29 (22.0)1.80 (1.16–2.79)1.82 (1.16–2.85)

Adjusted for age, diabetes mellitus, hypertension, coronary heart disease, hyperlipidemia, side effects, urbanization level, geographic region, and enrollee category.